News Release

September 4, 2025
JCR Pharmaceuticals Co., Ltd.

# Notice of Organizational and Personnel Changes

**Hyogo, Japan – September 4, 2025 –** JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR") announced today the following organizational and personnel changes.

1. Organizational Changes (As of October 1, 2025)

1. Japan Development Unit Established

JCR has established a **Japan Development Unit** to accelerate strategic drug development in the domestic market, respond swiftly to evolving regulatory trends and environmental changes, while also strengthening its domestic business foundation.

2. Quality Assurance Division Reorganized

To ensure consistent and effective quality management under a unified policy, JCR has integrated quality management functions previously held by the Quality Assurance Division and the Research Division. Three new departments — **GCP QA Department**, **GMP QA Department**, and **GMP QC Department** — have been created under the Quality Assurance Division to support this structure. As part of the reorganization, the existing Quality Assurance Department has been discontinued.

3. Research Division Reorganized

JCR has realigned parts of its Research Division to strengthen collaboration across CMC functions ahead of global regulatory submissions. The Analytical Development Unit, previously under the Analytical R&D Center, has been transferred to the CMC Development Laboratory and renamed the **Analytical Research Unit**. The QC Testing Unit has been integrated into the new GMP QC Department within the Quality Assurance Division and subsequently discontinued. As part of this reorganization, the Analytical R&D Center and the Research Management Department have been discontinued.

2. Personnel Changes (As of October 1, 2025)

| Name | New Title | Current Title |
|---|---|---|
| Tatsuyoshi Yamamoto | Unit Leader, Japan Development Unit | Unit Sub-Leader, Medical Affairs Unit, Development Division |
| Toshiya Tomitsuka | Director, GMP QA Department, Quality Assurance Division | Director, Quality Assurance Department, Quality Assurance Division |
| Karen Mac Kenna | Director, GCP QA Department, JCR Europe B.V.<br>Director, GCP QA Department, Quality Assurance Division | Director, GCP QA Department, JCR Europe B.V. |
| Takatoshi Tateyama | Director (alternate), GMP QC Department, Quality Assurance Division<br>Group Manager, QC Management Group | Manager of QCT Control Office, Unit Leader of QC Testing Unit, Analytical R&D Center, Research Division |

**About JCR Pharmaceuticals Co., Ltd.**

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including partners, patients and employees. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit JCR's global website: https://jcrpharm.com/.

**Contact:**
Investors & Media:
JCR Pharmaceuticals Co., Ltd.
Corporate Communications
ir-info@jp.jcrpharm.com

###